Efficacy and safety of bispecific antibodies in multiple myeloma patients with end-stage renal disease undergoing hemodialysis: a case report of elranatamab and a literature review

Abstract Recent advances in multiple myeloma (MM) treatment, including bispecific antibodies (BsAbs), have improved outcomes. Elranatamab, a BsAb targeting B-cell maturation antigen and CD3, has shown efficacy in relapsed/refractory MM (RRMM). However, its use in patients with end-stage renal diseas...

Whakaahuatanga katoa

Ngā taipitopito rārangi puna kōrero

Ngā kaituhi matua:	Daisuke Ogiya, Rikio Suzuki, Shun Goto, Yosuke Nakagawa, Miina Nasukawa, Shino Iwata, Hidetsugu Kawai, Masako Toyosaki, Shinichiro Machida, Makoto Onizuka, Yoshiaki Ogawa, Hiroshi Kawada
Hōputu:	Artigo
Reo:	Inglês
I whakaputaina:	Springer 2025-10-01
Rangatū:	Annals of Hematology
Ngā marau:	Multiple myeloma End-stage renal disease Hemodialysis Bispecific antibody Elranatamab
Urunga tuihono:	https://doi.org/10.1007/s00277-025-06689-0
Ngā Tūtohu:	Tāpirihia he Tūtohu Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!